The medicinal product is to be used for disinfection of the skin prior to invasive medical procedures.
BridgeBio Pharma, Inc announced topline results from Month 12 (Part A) of ATTRibute-CM, an ongoing global Phase III study investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).